Randomized controlled trial of vitamin d supplementation on toll-like receptor-2 (tlr-2) and toll-like receptor-4 (tlr-4) in tuberculosis spondylitis patients

J Orthop Surg Res. 2023 Dec 21;18(1):983. doi: 10.1186/s13018-023-04445-6.

Abstract

Background: Tuberculosis spondylitis accounts for approximately 50% of all cases of skeletal tuberculosis. Vitamin D plays a role in the immune system. Vitamin D helps in the activation of TLR-2 and TLR-4, which play a role in the process of tuberculosis infection. The objective of this study was to investigate the effect of oral supplementation with vitamin D on TLR-2 and TLR-4 levels in tuberculosis spondylitis patients.

Methods: The true Experiment Design Pretest-Posttest with Control Group (Pretest-Posttest with Control Group) was used for this research. TLR-2 and TLR-4 were measured by ELISA. Repeated ANOVA, ANOVA tests, and Kolmogorov-Smirnov normality tests on the SPSS program were used to statistically analyze the results.

Result: In the dose groups of 10,000 IU and 5000 IU, significant increases in the levels of vitamin D, TLR-2, and TLR-4 were observed at weeks 4 and 8 (p < 0.05). In the control group, there was no significant increase.

Conclusions: Vitamin D supplements can significantly increase TLR-2 and TLR-4 levels. Supplementation with vitamin D 10,000 IU/day for 8 weeks can increase vitamin D levels > 50 ng/dl to optimally act as an immunomodulator.

Keywords: TLR-2; TLR-4; Tuberculosis spondylitis; Vitamin D.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Dietary Supplements
  • Humans
  • Toll-Like Receptor 2
  • Toll-Like Receptor 4
  • Tuberculosis, Spinal* / drug therapy
  • Vitamin D
  • Vitamin D Deficiency*

Substances

  • Toll-Like Receptor 2
  • Toll-Like Receptor 4
  • Vitamin D